Davern Capital Partners, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Davern Capital Partners, LP reported 15 stock positions worth $586.5 million. Its top holding was Biontech SE-ADR (BNTX) at 12.0% of the portfolio, followed by Roivant Sciences (ROIV, 11.7%) and Royalty Pharma Class A (RPRX, 11.0%). Compared with Q1 2026, it opened 3 new positions, sold out of 5, added to 10 and reduced 2. The biggest buy was a new position in Alnylam Pharmaceuticals (ALNY) and the biggest sale an exit from Pfizer (PFE).
- Most Recent 13F
- Q2 2026
- Location
- NY, NY
- CIK
- 0002003147
- Portfolio Value
- $586.5M (Q2 2026)
- SEC Filing
- 0000905148-26-003614 ↗ filed Aug 13, 2026
Holdings Value
Holdings 15 stocks · $586.5M
| BNTX Biontech SE-ADR | 11.97% | 754,550 | $70.2M | Add +147.3% |
| ROIV Roivant Sciences Ltd. | 11.66% | 1,932,904 | $68.4M | Add +121.3% |
| RPRX Royalty Pharma PLC Class A | 11.05% | 1,155,809 | $64.8M | Add +122.3% |
| IONS Ionis Pharmaceuticals Inc. | 10.80% | 798,709 | $63.3M | Add +106.4% |
| INSM Insmed Inc. | 10.18% | 559,824 | $59.7M | Add +206.7% |
| REGN Regeneron Pharmaceuticals | 9.85% | 92,640 | $57.8M | Add +106.8% |
| LEGN Legend Biotech Corp.-ADR | 5.87% | 1,191,522 | $34.4M | Reduce -9.4% |
| ALNY Alnylam Pharmaceuticals Inc. | 5.80% | 113,085 | $34.0M | New |
| NTRA Natera Inc. | 5.51% | 118,975 | $32.3M | Reduce -17.4% |
| GPCR Structure Therapeutics Inc. | 4.08% | 446,059 | $23.9M | Add +252.7% |
| MLYS Mineralys Therapeutics Inc. | 3.95% | 858,753 | $23.2M | Add +92.0% |
| VERA Vera Therapeutics Inc. | 3.65% | 498,832 | $21.4M | New |
| GENB Generate Biomedicines Inc. | 2.37% | 824,679 | $13.9M | Add +39.4% |
| PRCT Procept Biorobotics Corp. | 1.79% | 464,920 | $10.5M | Add +78.0% |
| AVTX Avalo Therapeutics Inc. | 1.48% | 468,666 | $8.7M | New |
Portfolio Sells Q1 2026 → Q2 2026
| PFE Pfizer Inc. | Sold out | 0.00% | −12.28 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −7.02 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −6.88 |
| NTRA Natera Inc. | Reduce -17.4% | 5.51% | −2.39 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −2.39 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −1.62 |
| LEGN Legend Biotech Corp.-ADR | Reduce -9.4% | 5.87% | −0.66 |
Portfolio Buys Q1 2026 → Q2 2026
| ALNY Alnylam Pharmaceuticals Inc. | New | 5.80% | +5.80 |
| ROIV Roivant Sciences Ltd. | Add +121.3% | 11.66% | +5.03 |
| BNTX Biontech SE-ADR | Add +147.3% | 11.97% | +4.53 |
| RPRX Royalty Pharma PLC Class A | Add +122.3% | 11.05% | +4.21 |
| VERA Vera Therapeutics Inc. | New | 3.65% | +3.65 |
| IONS Ionis Pharmaceuticals Inc. | Add +106.4% | 10.80% | +2.83 |
| GPCR Structure Therapeutics Inc. | Add +252.7% | 4.08% | +2.41 |
| INSM Insmed Inc. | Add +206.7% | 10.18% | +1.99 |
| AVTX Avalo Therapeutics Inc. | New | 1.48% | +1.48 |
| MLYS Mineralys Therapeutics Inc. | Add +92.0% | 3.95% | +0.63 |
| REGN Regeneron Pharmaceuticals | Add +106.8% | 9.85% | +0.35 |
| GENB Generate Biomedicines Inc. | Add +39.4% | 2.37% | +0.34 |
| PRCT Procept Biorobotics Corp. | Add +78.0% | 1.79% | −0.00 |